IL-DURAVANT
19.4.2021 15:02:06 CEST | Business Wire | Press release
Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the food processing, packaging and material handling sectors, announced today that it has entered into a definitive agreement to acquire Foodmate, a leading manufacturer of poultry processing equipment dual-headquartered in Ball Ground, Georgia, and Numansdorp, the Netherlands. Foodmate’s automated secondary processing solutions for poultry are widely recognized as the gold standard in the industry.
“We are absolutely thrilled with this partnership,” said Mike Kachmer, President and CEO of Duravant. “Foodmate is the preferred provider of processing systems in the poultry processing industry globally. Combine that with their culture of laser-focused innovation and superior engineering expertise, Foodmate is a wonderful addition to the Duravant family.”
This partnership brings together two global engineered equipment leaders and extends Duravant’s ability to serve customers and partners in over 190 countries worldwide within the food processing sector.
“We’re excited to be a part of and collaborate with the Duravant family of world-class brands,” said Scott Hazenbroek, President of Foodmate US. “Duravant and Foodmate are clearly aligned with a shared culture and Duravant’s global footprint will assist us in continuing to deliver premium solutions, optimize yield, improve quality and reduce labor costs for our customers. Duravant’s lifecycle management via the company’s SupportPro services complements and enhances our existing field service offerings that will further increase customers’ productivity and efficiency goals.”
The Foodmate brand of processing machinery has been a competitive force in the full line processing of poultry for over 15 years. With a strategic global footprint featuring manufacturing and engineering hubs in Europe, demo and showroom facilities in the US and the Netherlands and sales and assembly in the US, Foodmate’s customers are further supported by a local presence in 55 countries. Foodmate’s deep engineering and development capabilities allow for the custom design of complete automated solutions from the weighing and grading of the poultry product, to the cutting and deboning process. Recognized for advanced technology around software for vision and grading capabilities using proprietary software, and R&D capabilities supported by deep application know-how, Foodmate continues to grow its global presence.
David Hazenbroek, President of Foodmate B.V. The Netherlands, said, “Foodmate has an installed base of over 900 units serving the largest poultry processing companies globally. By partnering with the Duravant companies, we look forward to continuously delivering on our customer-first approach to innovation and service excellence.”
About Duravant
Headquartered in Downers Grove, IL, Duravant is a global engineered equipment company with manufacturing, sales and service facilities throughout North America, Europe and Asia. Through their portfolio of operating companies, Duravant delivers trusted end-to-end process solutions for customers and partners through engineering and integration expertise, project management and operational excellence. With worldwide sales distribution and service networks, they provide immediate and lifetime aftermarket support to all the markets they serve in the food processing, packaging and material handling sectors. Duravant’s market-leading brands are synonymous with innovation, durability and reliability. For more information, visit www.duravant.com .
About Foodmate
Foodmate is a leading poultry processing equipment manufacturer based in The Netherlands. Founded by industry experts in early 2006, the company quickly expanded its worldwide distribution into North and South America with the launch of Foodmate US in 2010. Foodmate Brasil was then launched in 2015, followed by the launch of Foodmate Poland in 2017 and the acquisition of Foodmate UK in 2019. Foodmate has become the committed and reliable partner of major poultry processing companies worldwide. In 2017, Inc. magazine has ranked Foodmate US, Inc. No.#13 in the manufacturing sector on its 36th Annual List of America’s Fastest-Growing Private Companies, the Inc. 5000, the most prestigious ranking of the nation’s fastest-growing private companies. For Foodmate US. visit www.foodmateus.com . For Foodmate B.V. visit www.foodmate.nl .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005136/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
